Valuation: Celsion Corporation

Market Cap 6.85M 5.94M 5.56M 5.07M 9.54M 653M 9.7M 65.16M 25.53M 327M 25.72M 25.16M 1.09B P/E 2026 *
-0.48x
P/E 2027 * -0.72x
Enterprise Value 6.85M 5.94M 5.56M 5.07M 9.54M 653M 9.7M 65.16M 25.53M 327M 25.72M 25.16M 1.09B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Change 5-day change 1-year change 3-year change Capi.($)
-0.70%+24.68%+76.72%+103.05% 70.85B
-2.35%+3.71%+31.77%+63.89% 55.41B
-1.62%+34.25%+17.43%+491.04% 29.43B
-0.30%+18.51%+56.61%+4.86% 24.12B
0.00%+1.59%-15.06%-13.21% 23.31B
+0.05%+7.96%+44.21%-22.57% 18.37B
+9.77%+25.32%+252.40%+442.16% 16.99B
0.00%+10.84%+31.14%+628.97% 16.1B
-3.08%-8.34%+37.21%+138.52% 13.12B
Average +0.20%+390.71%+59.16%+204.08% 29.75B
Weighted average by Cap. -0.40%+349.16%+55.34%+164.90%

Financials

2026 *2027 *
Net sales - -
Net income -14.9M -12.91M -12.09M -11.03M -20.75M -1.42B -21.1M -142M -55.53M -711M -55.94M -54.72M -2.37B -22.7M -19.67M -18.42M -16.81M -31.63M -2.17B -32.16M -216M -84.62M -1.08B -85.24M -83.39M -3.62B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-